ES2555393T3 - Nuevos compuestos - Google Patents

Nuevos compuestos Download PDF

Info

Publication number
ES2555393T3
ES2555393T3 ES10838240.9T ES10838240T ES2555393T3 ES 2555393 T3 ES2555393 T3 ES 2555393T3 ES 10838240 T ES10838240 T ES 10838240T ES 2555393 T3 ES2555393 T3 ES 2555393T3
Authority
ES
Spain
Prior art keywords
thieno
pyridin
benzenesulfonamide
methyloxy
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10838240.9T
Other languages
English (en)
Spanish (es)
Inventor
Deborah Chen
Kiew Ching Lee
Lamont Roscoe Terrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Application granted granted Critical
Publication of ES2555393T3 publication Critical patent/ES2555393T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ES10838240.9T 2009-12-18 2010-12-16 Nuevos compuestos Active ES2555393T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US287798P 2001-04-30
US28779809P 2009-12-18 2009-12-18
PCT/US2010/060696 WO2011075559A1 (en) 2009-12-18 2010-12-16 Novel compounds

Publications (1)

Publication Number Publication Date
ES2555393T3 true ES2555393T3 (es) 2015-12-30

Family

ID=44167691

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10838240.9T Active ES2555393T3 (es) 2009-12-18 2010-12-16 Nuevos compuestos

Country Status (5)

Country Link
US (1) US9029545B2 (enExample)
EP (1) EP2512242B8 (enExample)
JP (1) JP5799024B2 (enExample)
ES (1) ES2555393T3 (enExample)
WO (1) WO2011075559A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501846A1 (en) * 2010-04-02 2013-02-04 Firmenich Incorporated Sweet flavor modifier
RU2617700C2 (ru) 2011-08-12 2017-04-26 Синомикс, Инк. Производные 4-аминохинолин-3-карбоновой кислоты и содержащие их композиции для усиления сладкого вкуса
US9908893B2 (en) 2013-06-11 2018-03-06 Latvian Institute Of Organic Synthesis Thieno [2,3-b] pyridines as multidrug resistance modulators
JP6466092B2 (ja) * 2014-07-17 2019-02-06 ナオ・シング株式会社 枕による寝姿勢の調整方法および調整枕
BR112017008738B1 (pt) 2014-11-07 2021-06-15 Firmenich Incorporated Ácidos 4-amino-5-(ciclohexilóxi)quinolina-3-carboxílicos substituídos como modificadores de sabores adoçantes
WO2019023651A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
CN100343255C (zh) * 2002-04-23 2007-10-17 盐野义制药株式会社 吡唑并[1,5-a]嘧啶衍生物和含有该衍生物的NAD(P)H氧化酶抑制剂
EP1598354A1 (en) * 2004-05-18 2005-11-23 Vasopharm Biotech GmbH Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation
AR056200A1 (es) 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
EP2002835A1 (en) * 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

Also Published As

Publication number Publication date
EP2512242B8 (en) 2015-12-09
JP2013514384A (ja) 2013-04-25
US9029545B2 (en) 2015-05-12
US20120252805A1 (en) 2012-10-04
EP2512242B1 (en) 2015-09-30
WO2011075559A1 (en) 2011-06-23
JP5799024B2 (ja) 2015-10-21
EP2512242A1 (en) 2012-10-24
EP2512242A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
ES2969616T3 (es) Derivados de benzisoxazol sulfonamida
ES2317231T3 (es) Fenilaminopirimidinas sustituidas con hetariloxi como inhibidores de la rho-quinasa.
ES2672530T3 (es) Amidas heterocíclicas como inhibidores de cinasas
ES2935746T3 (es) Inhibidores de desmetilasa-1 específica de lisina
ES2632774T3 (es) Inhibidores de bromodominio de benzo[c]isoxazoloazepina y usos de los mismos
ES2962367T3 (es) Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
ES2761332T3 (es) Compuestos y composiciones como inhibidores de la cinasa c-kit
ES2907622T3 (es) Compuestos de heteroarilo como inhibidores de BTK y usos de estos
ES2433230T3 (es) Compuestos bicíclicos novedosos de urea
ES2544082T3 (es) Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso
ES2842876T3 (es) Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer
ES2948782T3 (es) Inhibidores de la desmetilasa 1 específica de lisina
ES2951212T3 (es) Fenilacetamidas como inhibidores de ROCK
ES2944304T3 (es) Pirazol azinas de ácido ciclohexílico como antagonistas de LPA
ES2555393T3 (es) Nuevos compuestos
ES2924704T3 (es) Pirazol azoles del ácido ciclohexílico como antagonistas de LPA
ES2770693T3 (es) Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
BRPI0708615A2 (pt) compostos de pirazol heterobicìclicos e métodos de uso
BRPI0618668A2 (pt) composto, composição, método pra o tratamento de uma doença hiperproliferativa em um mamìfero, uso de um composto e método para a preparação de um composto
CA2909310A1 (en) Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways
BR112015004489B1 (pt) Composto, composição farmacêutica, e, uso de um composto
BR122012012032A2 (pt) Usos de inibidores de cinase úteis para preparação de composições farmacêuticas utilizáveis no tratamento de doenças proliferativas
CA3138300A1 (en) Inhibitors of raf kinases
CN111471059B (zh) Pde9抑制剂及其用途
AU2017372377B2 (en) Imidazo [1,5-a] pyrazine derivatives as PI3Kdelta inhibitors